These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36194203)

  • 1. Knowledge of Bladder Cancer Risk Factors Among Patients Diagnosed With Nonmuscle-invasive Bladder Cancer.
    Matulewicz RS; Whiting K; Bochner BH; Ostroff JS; Furberg H
    J Urol; 2023 Jan; 209(1):6-8. PubMed ID: 36194203
    [No Abstract]   [Full Text] [Related]  

  • 2. Examining the Accuracy of Self-Reported Smoking-Related Exposure among Recently Diagnosed Nonmuscle Invasive Bladder Cancer Patients.
    Petruzella S; Bochner BH; Kenney J; Whiting K; Sadeghi K; Benfante N; Cha EK; Dalbagni G; Donahue T; Donat SM; Herr HW; Pietzak E; Orlow I; Ostroff JS; Furberg H
    J Urol; 2021 May; 205(5):1321-1325. PubMed ID: 33356484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer.
    Sanchez A; Wszolek MF; Niemierko A; Clayman RH; Drumm M; Rodríguez D; Feldman AS; Dahl DM; Heney NM; Shipley WU; Zietman AL; Efstathiou JA
    J Urol; 2018 Feb; 199(2):407-415. PubMed ID: 28870862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder cancer--current management.
    Arianayagam R; Arianayagam M; Rashid P
    Aust Fam Physician; 2011 Apr; 40(4):209-13. PubMed ID: 21597531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. American Urological Association Nonmuscle Invasive Bladder Cancer Risk Model Validation-Should Patient Age be Added to the Risk Model?
    Ravvaz K; Weissert JA; Downs TM
    J Urol; 2019 Oct; 202(4):682-688. PubMed ID: 31188732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prevalence of Bladder Cancer During Cystoscopy for Asymptomatic Microscopic Hematuria.
    Gonzalez AN; Lipsky MJ; Li G; Rutman MP; Cooper KL; Weiner DM; Badalato G; Decastro GJ; Wenske S; McKiernan JM; Anderson CB
    Urology; 2019 Apr; 126():34-38. PubMed ID: 30677457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guérin Failure and Improves Patient Stratification at Diagnosis.
    de Jong FC; Hoedemaeker RF; Kvikstad V; Mensink JTM; de Jong JJ; Boevé ER; van der Schoot DKE; Zwarthoff EC; Boormans JL; Zuiverloon TCM
    J Urol; 2021 Mar; 205(3):701-708. PubMed ID: 33191862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-risk nonmuscle invasive bladder cancer: definition and epidemiology.
    Porten SP; Cooperberg MR
    Curr Opin Urol; 2012 Sep; 22(5):385-9. PubMed ID: 22842681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bladder cancer in Spain 2011: population based study.
    Miñana B; Cózar JM; Palou J; Unda Urzaiz M; Medina-Lopez RA; Subirá Ríos J; de la Rosa-Kehrmann F; Chantada-Abal V; Lozano F; Ribal MJ; Rodríguez Fernández E; Castiñeiras Fernández J; Concepción Masip T; Requena-Tapia MJ; Moreno-Sierra J; Hevia M; Gómez Rodríguez A; Martínez-Ballesteros C; Ramos M; Amón Sesmero JH; Pizá Reus P; Bohorquez Barrientos A; Rioja Sanz C; Gomez-Pascual JA; Hidalgo Zabala E; Parra Escobar JL; Serrano O
    J Urol; 2014 Feb; 191(2):323-8. PubMed ID: 23994371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer.
    Chen CH; Shun CT; Huang KH; Huang CY; Tsai YC; Yu HJ; Pu YS
    BJU Int; 2007 Aug; 100(2):281-6; discussion 286. PubMed ID: 17419696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer.
    Hendricksen K; Witjes JA
    Curr Opin Urol; 2007 Sep; 17(5):352-7. PubMed ID: 17762630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed for nonmuscle invasive bladder cancer.
    Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Donat SM; Bochner BH; Dalbagni G
    J Urol; 2013 Oct; 190(4):1187-91. PubMed ID: 23680310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer.
    Arends TJ; van der Heijden AG; Witjes JA
    J Urol; 2014 Sep; 192(3):708-13. PubMed ID: 24704017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.
    Ravvaz K; Walz ME; Weissert JA; Downs TM
    J Urol; 2017 Oct; 198(4):824-831. PubMed ID: 28433642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer.
    Rink M; Xylinas E; Babjuk M; Hansen J; Pycha A; Comploj E; Lotan Y; Sun M; Karakiewicz PI; Abdennabi J; Fajkovic H; Loidl W; Chun FK; Fisch M; Scherr DS; Shariat SF
    J Urol; 2012 Dec; 188(6):2120-7. PubMed ID: 23083868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.
    Brausi M; Witjes JA; Lamm D; Persad R; Palou J; Colombel M; Buckley R; Soloway M; Akaza H; Böhle A
    J Urol; 2011 Dec; 186(6):2158-67. PubMed ID: 22014799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study.
    Geijsen ED; de Reijke TM; Koning CC; Zum Vörde Sive Vörding PJ; de la Rosette JJ; Rasch CR; van Os RM; Crezee J
    J Urol; 2015 Nov; 194(5):1202-8. PubMed ID: 26143111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition.
    Lamm D; Persad R; Brausi M; Buckley R; Witjes JA; Palou J; Böhle A; Kamat AM; Colombel M; Soloway M
    J Urol; 2014 Jan; 191(1):20-7. PubMed ID: 23973937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies.
    Richards KA; Smith ND; Steinberg GD
    J Urol; 2014 Jun; 191(6):1655-64. PubMed ID: 24518761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of heterozygosis on IFN-alpha locus is a prognostic indicator of bacillus Calmette-Guerin response for nonmuscle invasive bladder cancer.
    Cai T; Nesi G; Dal Canto M; Tinacci G; Mondaini N; Piazzini M; Geppetti P; Bartoletti R
    J Urol; 2010 May; 183(5):1738-43. PubMed ID: 20299058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.